
NovaBridge Biosciences (NBP) Stock Forecast & Price Target
NovaBridge Biosciences (NBP) Analyst Ratings
Bulls say
NovaBridge Biosciences is a promising biotechnology platform with a potential in-class CLDN18.2 bispecific antibody, givastomig, for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies. The company's strong immuno-oncology pipeline, including givastomig, uliledlimab, and ragistomig, and its successful combination therapy results with opdivo and chemotherapy in 1L HER2-negative metastatic gastric cancer patients, showcase its potential for future success. Additionally, NovaBridge's prudent financial management and commitment to givastomig's development and focus on US investors suggest a positive long-term outlook.
Bears say
NovaBridge Biosciences is poised for potential success with its strong pipeline of three clinical stage programs, including potential in-class bispecific antibody givastomig for the treatment of gastric cancer and other gastrointestinal malignancies. With FDA endorsement and improved tolerability, the company's givastomig is expected to integrate well into traditional chemo-IO backbone regimens, leading to potential accelerated timelines and bolstering global confidence in NovaBridge's restructured platform. This positive feedback and guidance from the FDA is expected to be a major leverage for the company in the future.
This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.
NovaBridge Biosciences (NBP) Analyst Forecast & Price Prediction
Start investing in NovaBridge Biosciences (NBP)
Order type
Buy in
Order amount
Est. shares
0 shares